Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 1.00 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL17978250 | 0.95 | PARP1 (0.90) | PARP1HCRTR1HCRTR2AURKAMGLL | |
| SCHEMBL17978285 | 0.91 | PARP1 (0.84) | PARP1HCRTR1HCRTR2AURKAHSD17B10 | |
| Hydrochloric Acid SCHEMBL17978158 | 0.90 | PARP1 (0.81) | PARP1HCRTR1HCRTR2AURKAHSD17B10 | |
| SCHEMBL729580 | 0.85 | PARP1 (0.74) | PARP1HCRTR1HCRTR2MGLLRORC | |
| Hydrochloric Acid SCHEMBL7265489 | 0.84 | PARP1 (0.72) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL1021074 | 0.84 | PARP1 (0.72) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL3360298 | 0.84 | PARP1 (0.72) | PARP1HCRTR1HCRTR2MGLLRORC | |
| Cadaverine Tartrate SCHEMBL20968877 | 0.82 | PARP1 (0.68) | PARP1HCRTR1HCRTR2AURKAMGLL | |
| SCHEMBL21804730 | 0.82 | PARP1 (0.70) | PARP1HCRTR1HCRTR2MGLLRORC | |
| SCHEMBL10713556 | 0.81 | PARP1 (0.69) | PARP1HCRTR1HCRTR2MGLLRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | claimed |
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | claimed |
| CN-115515933-A | Translumenally acting N- (piperidin-4-yl) benzamide derivatives | 武田药品工业株式会社 | 2022-12-23 | — | — | CN | claimed |
| CN-114867495-A | Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome | 日本新药株式会社 | 2022-08-05 | — | — | CN | claimed |
| CN-114845735-A | Antitumor drug combined with immune checkpoint inhibitor | 日本新药株式会社 | 2022-08-02 | — | — | CN | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| CN-119899178-A | Aromatic amide derivative, preparation method thereof and application thereof in medicine | 浙江海正药业股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| WO-2025067239-A1 | KINESIN KIF18A INHIBITOR, AND APPLICATION THEREOF | 上海湃隆生物科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119303087-A | Preventive and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome | 日本新药株式会社 | 2025-01-14 | — | — | CN | disclosed |
| US-20250011288-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-01-09 | — | — | US | disclosed |
| EP-3210626-B1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | BIOLITEC HOLDING GMBH & CO KG (AT) | 2024-11-27 | — | — | EP | disclosed |
| CN-114867495-B | Preventive and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome | 日本新药株式会社 | 2024-10-18 | — | — | CN | disclosed |
| US-5175173-A | Reduced side effects | SUN JUNG HUI (US) | 1992-12-29 | — | — | US | disclosed |
| US-5126364-A | Antiemetics, antipsychotics | ERBAMONT, INC. (US) | 1992-06-30 | — | — | US | disclosed |
| EP-0234872-B1 | CARBOXAMIDES USEFUL AS ANTIEMETIC OR ANTIPSYCHOTIC AGENTS | Erbamont Inc. (US) | 1991-11-27 | — | — | EP | disclosed |
| EP-0147044-B1 | BENZOFURANCARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | ADRIA LABORATORIES INC. (US) | 1990-04-25 | — | — | EP | disclosed |
| US-4888353-A | Carboxamides useful as antiemetic or antipsychotic agents | ERBAMONT, INC. (US) | 1989-12-19 | — | — | US | disclosed |
| EP-0234872-A1 | Carboxamides useful as antiemetic or antipsychotic agents | Erbamont Inc. (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0147044-A2 | Benzofurancarboxamides, process for their preparation and pharmaceutical preparations containing them | ADRIA LABORATORIES INC. (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011288-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | PARP1 4544/4885HCRTR1 661/4885HCRTR2 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.